Related Experiment Video
Updated: May 23, 2026
Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis
Published on: October 27, 2023
Corticoids Reduce Incidence of Oral Mucositis during Antineoplastic Treatment? A Systematic Review and Meta-Analysis
Ana Beatriz Silva Marques Araújo1,2, Jennifer Vianna Barbosa1, Giulianna Aparecida Vieira Barreto1
1Hospital Haroldo Juaçaba, Ceará Cancer Institute, Fortaleza, Ceará, Brazil.
Background:
Oral mucositis (OM) is a serious complication of antineoplastic therapy and its clinical presentation can range from small erythematous lesions to large, debilitating ulcerative areas. This adverse effect results from the non-specificity of chemotherapeutic agents. This study aims to determine whether corticosteroid protocols reduce the incidence or severity of OM during antineoplastic treatment.
Materials And Methods:
This PROSPERO registered systematic review (CRD42023442448) searched PubMed, Scopus, Web of Science, LILACS, EBSCOhost, LIVIVO, Embase, and the gray literature. RoB-2 and ROBINS-I were used to assess the risk of bias (RoB), and a meta-analysis was performed evaluating the incidence or severity of OM. GRADE-pro analyzed the certainty of the evidence.
Results:
Of the 1795 articles, 5 RCTs and three n-RCTs were included, involving 718 patients, 255 men and 463 women distributed among 379 patients in the intervention groups and 339 patients in the control groups. High heterogeneity and low publication RoB were identified. The topical application of corticosteroids did not impair OM incidence (p=0.860). However, the systemic application of corticosteroids resulted in a reduction of 0.44 (CI95% = 0.29 to 0.66) times (p<0.001). There is no significant risk of publication bias (p=0.881). In the meta-analysis of OM severity, topical (p=0.280) or systemic (p=0.270) application did not show a significant reduction in the MO scores; there was no significant heterogeneity (p=0.940, I²=0%), and leave-one-out analysis demonstrated that removing individual study results did not alter this outcome. GRADE showed moderate certainty for both OM incidence and severity. Inconsistency and imprecision were low to moderate, and the risk of publication bias was low.
Conclusion:
High doses of systemic corticosteroids demonstrate clinical benefits in controlling OM, while the topical use requires further investigation, particularly with high-potency formulations.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...